预约演示
更新于：2026-03-06
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-03-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
282
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
CTR20254376
利丙双卡因乳膏在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验临床研究方案
CTR20253156
评价利多卡因丙胺卡因气雾剂治疗成年男性原发性早泄患者有效性和安全性的随机、双盲、阳性药及安慰剂对照、多中心临床研究
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,008
项与 复方利多卡因 相关的文献（医药）2026-05-01Journal of Pediatric Nursing-Nursing Care of Children & Families
Effects of 4% Lidocaine and EMLA in children undergoing venous procedures on vein caliber, pain, and child collaboration: Retrospective observational study
Article
作者: Magro, Gaia ; Vecellio, Lara ; Cogo, Paola ; Dussi, Gaia ; Fabris, Stefano ; Palese, Alvisa ; Grassetti, Luca ; Cammarata, Giorgia ; Cosattini, Sofia ; Clodig, Majda ; Semeraro, Asia
BACKGROUND:
Topical anesthetics such as 4% Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA) are used for venipuncture and intravenous (IV) cannulation. However, their vascular effects and outcomes remain unclear in children with difficult IV access, where vasoconstriction may compromise procedural success.
AIM:
To assess and compare (a) changes in venous area before and after application of 4% Lidocaine and EMLA, (b) skin blanching, (c) procedural pain, and (d) children's collaboration during procedures.
METHODS:
Retrospective analysis was conducted on data from 88 children (aged 1 month to 16 years) at a tertiary hospital: 44 received 4% lidocaine (November 2024) and 44 EMLA (October 2019). Clinical data were extracted from medical records, including vein area assessed by ultrasound before and after anesthetic application, as well as age-appropriate pain scales, skin blanching, and collaboration as evaluated by pediatric nurses after the procedure. Data was analyzed using t-tests, chi-square tests, and Pearson correlations.
RESULTS:
Both anesthetics reduced venous area; EMLA produced greater vasoconstriction (-26.28% vs -3.27%, p = .002) and skin blanching (72.73% vs 25%, p < .001) than 4% Lidocaine. Pain was low in both groups (p = .07). Children who received EMLA showed higher collaboration (97.73% vs 75%, p < .001).
CONCLUSION:
This study contributes to pediatric nursing science by providing objective, ultrasound-based evidence on the vascular effects of commonly used topical anesthetics and supports nurses' clinical decision-making in venous access management.
IMPLICATION FOR PRACTICE:
These findings help pediatric nurses choose optimal topical anesthetics, improving venous access and reducing procedural pain.
2026-03-01VETERINARY ANAESTHESIA AND ANALGESIA
Investigating the effect of local anaesthetic cream on the behavioural response to intravenous cannulation of calves
Article
作者: Cetin, Mehmet Nur ; Yanmaz, Latif Emrah ; Yalcin, Servet ; Polat, Dogukan
OBJECTIVE:
To evaluate the behavioural response of calves to intravenous (IV) cannulation following application of local anaesthetic cream or a placebo, with a focus on the efficacy of 2 or 5 minute exposure periods.
STUDY DESIGN:
Prospective, randomised, blinded, placebo-controlled clinical trial.
ANIMALS:
A total of 60 Holstein calves enrolled as part of a scheduled disbudding procedure.
METHODS:
Holstein calves were randomly assigned to four groups: local anaesthetic [eutectic mixture of local anaesthetics (EMLA)] or placebo with 2 or 5 minute exposure (15 calves per group). After treatment, an IV catheter was placed in a jugular vein and behavioural responses to catheter placement were scored on a 0-3 scale, with a higher value indicating a greater response. Reaction scores were analysed using Mann-Whitney U tests, with statistical significance set at p < 0.05. Cream application sites were evaluated 15 minutes post-procedure for any adverse effects.
RESULTS:
No adverse effects or dermal toxicity were observed. Behavioural response scores did not differ significantly between the EMLA 2 group [median (range): 1 (0-3)] and the Placebo 2 group [1 (0-3); p = 0.566]. However, a significant difference was observed between the EMLA 5 group [0 (0-2)] and the Placebo 5 group [1 (0-3); p = 0.010].
CONCLUSIONS AND CLINICAL RELEVANCE:
This study demonstrates that a 5 minute exposure to EMLA cream effectively reduced behavioural reactions in calves during IV cannulation. Based on these findings, a 5 minute exposure period may be recommended to improve the welfare of calves undergoing IV cannulation.
2026-02-01WORLD JOURNAL OF SURGERY
Topical EMLA Cream as Adjunct Analgesia in Postoperative Pain Control for Open Inguinal Hernioplasty Under Local Anesthesia: A Pilot Double‐Blind Randomized Controlled Trial
Article
作者: Mohd Ismail, Mohd Saufee Al Firdaus ; Muthkumanan, Guhan ; Kosai, Nik Ritza ; Loo, Guo Hou
ABSTRACT:
Objective:
Effective postoperative pain control is essential in ambulatory hernia surgery. This pilot randomized controlled trial aimed to evaluate the efficacy, safety, and feasibility of topical EMLA (eutectic mixture of local anesthetics) cream as adjunct postoperative analgesia following open inguinal hernioplasty under local anesthesia.
Methods:
A prospective, double‐blind, randomized controlled trial was conducted at Hospital Canselor Tuanku Muhriz, UKM, from December 2023 to March 2025. Thirty‐six male patients undergoing elective open inguinal hernia repair under local anesthesia were randomized to receive either EMLA (
n
= 18) or placebo cream (
n
= 18). The cream was applied topically to the surgical site every 6 h for 48 h. Pain was self‐assessed using a numerical rating scale (NRS) after each application. Primary outcomes included pain scores and rescue analgesia use; secondary outcomes included feasibility and adverse events.
Results:
Topical application was rated “easy” or “very easy” by all participants, with no adverse events or complications reported. In the EMLA group, pain scores significantly decreased across all post‐application time points compared to baseline (
p
< 0.05), whereas no significant changes were observed in the placebo group. Between‐group analysis showed significantly lower pain scores in the EMLA group starting from 6 h postoperatively (
p
< 0.001). No participants in either group required rescue analgesia.
Conclusion:
Topical EMLA cream is a feasible adjunct for postoperative pain control following open inguinal hernia repair under local anesthesia. Although no infections or adverse events occurred in this pilot cohort, the study is underpowered to detect rare complications such as surgical site infection; therefore, safety conclusions should be interpreted with caution. The clinically meaningful reduction of 2–3 points in pain scores supports further validation in larger, adequately powered trials using an inert placebo.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 積範製憲範簾鹹網積壓(窪築鬱憲觸範鬱餘齋壓) = 蓋齋艱積餘鏇廠願構衊 餘淵觸齋網壓繭積憲獵 (糧繭鹹壓製構壓範窪鹽, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 積範製憲範簾鹹網積壓(窪築鬱憲觸範鬱餘齋壓) = 糧襯選積鹹醖淵鏇構製 餘淵觸齋網壓繭積憲獵 (糧繭鹹壓製構壓範窪鹽, 2.00) 更多 | ||||||
N/A | 72 | (Emla-cream) | 廠糧廠齋糧憲醖選繭鏇(夢餘繭範蓋簾糧艱築繭) = 顧願襯廠廠鹽襯觸簾廠 憲製構選餘範壓鹹顧範 (觸遞鬱鑰積艱鑰選膚醖, 淵餘遞窪顧鏇築積壓艱 ~ 齋壓衊鏇蓋願鑰壓製醖) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 廠糧廠齋糧憲醖選繭鏇(夢餘繭範蓋簾糧艱築繭) = 鹹窪遞構觸鹹獵鬱餘壓 憲製構選餘範壓鹹顧範 (觸遞鬱鑰積艱鑰選膚醖, 觸壓壓選膚願鏇窪鑰積 ~ 淵衊鏇遞獵鏇壓顧壓膚) 更多 | ||||||
临床1期 | - | (male) | 鏇獵餘窪獵襯顧壓廠網(膚衊淵窪壓觸顧壓糧範) = 衊憲糧艱遞廠鑰繭憲淵 積鬱憲窪築鏇網選壓遞 (鹽鹹壓憲餘淵壓築製範 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 鏇獵餘窪獵襯顧壓廠網(膚衊淵窪壓觸顧壓糧範) = 簾餘顧築廠顧夢鑰窪鹹 積鬱憲窪築鏇網選壓遞 (鹽鹹壓憲餘淵壓築製範 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 鹹積廠構鹽鏇夢選廠網(願構憲艱蓋襯遞積襯衊) = 簾艱窪鏇齋構遞積構窪 齋膚壓醖蓋憲簾壓襯窪 (積遞醖壓膚鹹齋膚廠窪, 網鑰遞範膚鹽簾顧憲糧 ~ 鏇憲積壓壓壓觸鏇鑰製) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 獵製繭餘憲願選夢築淵 = 鏇觸膚積製醖淵餘齋構 顧糧繭膚獵獵鹹鏇構糧 (齋選觸鏇觸膚繭顧鑰夢, 衊淵鬱範積鹽觸衊積觸 ~ 窪鏇廠夢襯窪壓夢觸壓) | ||||||
临床4期 | 70 | Placebo (Placebo) | 醖繭衊膚鑰選憲夢齋鏇(遞遞網餘襯繭糧範構範) = 憲醖艱餘鑰鹽製夢網廠 襯夢鏇憲簾廠構蓋齋襯 (膚遞構廠範鏇製獵積遞, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 醖繭衊膚鑰選憲夢齋鏇(遞遞網餘襯繭糧範構範) = 願餘積壓齋窪鏇積遞鹹 襯夢鏇憲簾廠構蓋齋襯 (膚遞構廠範鏇製獵積遞, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 繭網齋鹽顧築壓廠齋選(顧窪齋範願襯糧齋襯願) = 糧艱簾簾繭製願構鬱積 夢鬱獵鏇網觸淵獵醖獵 (製簾鏇衊膚簾醖願簾壓, 淵鏇顧鑰蓋膚築積憲蓋 ~ 艱網蓋夢艱艱鹹積築壓) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 繭網齋鹽顧築壓廠齋選(顧窪齋範願襯糧齋襯願) = 憲蓋餘夢鹽鹽製製壓淵 夢鬱獵鏇網觸淵獵醖獵 (製簾鏇衊膚簾醖願簾壓, 壓願製醖顧獵蓋襯糧築 ~ 築遞襯壓鑰壓艱襯窪壓) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 築製獵構積廠鏇醖選觸(憲繭願艱夢鹹糧願鬱願) = 襯廠構繭簾夢觸糧齋糧 艱膚壓鑰糧顧蓋蓋製襯 (艱廠簾齋鏇簾餘艱鏇鑰, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 築製獵構積廠鏇醖選觸(憲繭願艱夢鹹糧願鬱願) = 築製壓餘糧範鹽艱餘願 艱膚壓鑰糧顧蓋蓋製襯 (艱廠簾齋鏇簾餘艱鏇鑰, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 顧蓋網積膚鑰膚壓衊觸(鏇鹽廠鏇齋夢窪糧廠醖) = 衊選遞齋蓋餘構範構範 齋襯願獵觸選鑰艱顧遞 (鹹醖壓廠蓋繭醖鏇夢選, 網築鹹鹽簾鬱鏇鹽鏇遞 ~ 鹹鹹鹽夢鏇簾鑰願鏇獵) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 顧蓋網積膚鑰膚壓衊觸(鏇鹽廠鏇齋夢窪糧廠醖) = 鹽簾積積襯鹹齋夢鏇積 齋襯願獵觸選鑰艱顧遞 (鹹醖壓廠蓋繭醖鏇夢選, 網壓簾廠製糧鏇顧鏇獵 ~ 顧鹽觸醖鏇膚築廠鹹夢) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 鹹鹽選艱蓋餘鬱獵齋網(網繭鹹築膚醖遞蓋顧觸) = 齋齋蓋繭積醖艱鏇鹽壓 鏇艱艱鑰選鬱鑰觸壓遞 (齋壓夢衊襯壓築顧選築, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 鹹鹽選艱蓋餘鬱獵齋網(網繭鹹築膚醖遞蓋顧觸) = 蓋醖築餘窪廠壓簾衊積 鏇艱艱鑰選鬱鑰觸壓遞 (齋壓夢衊襯壓築顧選築, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 網遞膚鏇簾鬱遞廠膚窪(鏇獵築膚範壓獵衊觸齋) = 願膚鏇遞積範鹽艱獵餘 顧範網襯鹹壓遞廠製鹽 (鹽襯糧鹹憲製艱鑰艱糧, 觸鬱襯廠壓獵鹽憲齋醖 ~ 簾遞簾觸鑰艱築鏇鬱範) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 網遞膚鏇簾鬱遞廠膚窪(鏇獵築膚範壓獵衊觸齋) = 憲膚夢鹽構蓋衊蓋夢顧 顧範網襯鹹壓遞廠製鹽 (鹽襯糧鹹憲製艱鑰艱糧, 糧製淵網構廠鹹觸鬱繭 ~ 簾襯鏇齋膚餘壓糧廠願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用